[1]顾宏涛.细胞防护剂WR-2721研究进展[J].国际放射医学核医学杂志,2003,27(3):135-137.
 GU Hong-tao.Advances in research of the cytoprotector WR-2721[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(3):135-137.
点击复制

细胞防护剂WR-2721研究进展(/HTML)
分享到:

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
27
期数:
2003年第3期
页码:
135-137
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Advances in research of the cytoprotector WR-2721
作者:
顾宏涛
710032 陕西西安, 第四军医大学西京医院血液科
Author(s):
GU Hong-tao
Department of Xijing Hospital, The Fourth Military Medical University, Shanxi Xian 710032, China
关键词:
amifostine放射疗法化学疗法辐射防护
Keywords:
WR-2721 (amifostine)radiotherapychemotherapyradiation protection
分类号:
R730.1
摘要:
WR-2721(amifostine)是一种广谱的细胞保护剂,在体内通过其活性形式WR-1065保护正常细胞,减轻放、化疗毒副作用,促进造血细胞恢复,使患者可以耐受大剂量放、化疗。WR-2721可能成为高恶性和耐药性肿瘤治疗新策略之一。
Abstract:
WR-2721 (amifostine)is a broad-spectrum cytoprotector. Its active metabolite-WR1065 can protect normal cell, reduce the toxicities of radiotherapy and chemotherapy and improve hematoiogic cell. As a result, the patients may tolerate the high dose of chemo-radiotherapy. WR-2721 may be a new way on the therapies of the high-advanced and the multidrug resistant tumor.

参考文献/References:

[1] Savoye C, Swenberg C, Hugot S,et al. Thiol WR-1065 and disulfide WR-33278, two metabolites of the drug Ethol (WR-2721), protect DNA against fast neutron induced strand breakage[J]. Int J Radiat Biol, 1997, 71:193-202.
[2] North S, El-Ghissassi F, Verdaegh G, et al. The cytopro-tective aminothiol WR-1065 activates p21 wat-1 and down regulates cell cycle progression through a p53-dependent pathway[J].Oncogene, 2000, 19(9):1206-1214.
[3] Snyder RD, Grdina DJ. Further evidence that the radiopro-tectibve aminothiol, WR-1065, cataly inactivates mammalian topoisomerase 2[J]. Cancer Res, 2000, 60:1186-1188.
[4] Momm F, Bechtold C, Rudat V, et al. Alteration of radiation-induced hematotoxicity by manifesting[J]. Int J Radiat Oncol Biol Phys, 2001, 51(4):947-951.
[5] Fulda S, Fichtner I, Hero B, et al. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients[J]. Med Pediatr Oncol, 2001, 36(1):199-202.
[6] Antonadou D, Coliarakis N, Synodinou M, et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer[J]. Int J Radiat Oncol Biol Phys, 2001,51(4):915-922.
[7] Jahnukainen K, Jahnukainen T, Salmi TT, et al. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats[J]. Cancer Res, 2001, 61:6423-6427.
[8] Koukourakis MI, Romanidis K, Froudarakis M, et al. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer:excellent tolerance using subcutaneous amifostine for cytoprotection[J]. Br J Cancer, 2002, 87(4):385-392.
[9] Michieli M, Michelutti A, Damiani D, et al. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines[J]. Leuk Lymphoma, 2001,42(4):721-729.
[10] Galanopoulos A, Kritikou-Griva E, Gligori J, et al. Treatment of patients with myelodysplastic syndrome with manifesting[J]. Leuk Res, 2001, 25(8):665-671.
[11] Yilmaz A, Kaufmann CC, Binder C, et al. Effects of amifos-tine in a patient with an advanced-stage myelodysplastic syndrome[J]. Ann Hematol, 2001, 80(1):53-57.
[12] Rick O, Schwella N, Beyer J, et al. PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine:results of a prospective randomized trial[J]. Transfusion, 2001,41(2):196-200.
[13] Kuittinen O, Ruokolainen H, Turpeenniemi-Hujanen T. Amifostine does not protect malignant lymphoma cell lines from the cytotoxic effects of various chemotherapeutics invitro[J]. Leuk Lymphoma, 2001, 42(3):507-510.
[14] Genvresse I, Lange C, Schanz J, et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy:a comparative study[J]. AnticancerDrugs, 2001,12(4):345-349.

相似文献/References:

[1]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
 Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[2]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
 Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[3]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
 Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[4]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
 Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[5]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
 Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[6]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
 Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
 zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
 Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]段永璇,邹晓艳,段秀梅,等.数据解析在肿瘤放射治疗中的应用[J].国际放射医学核医学杂志,2015,39(6):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
 Duan Yongxuan,Zou Xiaoyan,Duan Xiumei,et al.Data analysis in the field of tumor radiation therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):505.[doi:10.3760/cma.j.issn.1673-4114.2015.06.015]
[10]贾立立,孟粹达,刘晓冬,等.头颈部肿瘤放疗中转化医学相关机制的研究进展[J].国际放射医学核医学杂志,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]
 Jia Lili,Meng Cuida,Liu Xiaodong,et al.Development in translational medicine-related mechanisms of radiotherapy for head and neck cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):247.[doi:10.3760/cma.j.issn.1673-4114.2015.03.013]

备注/Memo

备注/Memo:
收稿日期:2002-12-03。
作者简介:顾宏涛(1974-),男,硕士研究生,主要从事造血细胞保护方面研究。
更新日期/Last Update: 1900-01-01